Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412780 | 0.87 | TSHR (0.56) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2111020 | 0.86 | KMT2A (0.65) | MEN1KMT2ATSHRALDH1A1MAOB | |
| SCHEMBL28336064 | 0.86 | TSHR (0.54) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL27424330 | 0.86 | TSHR (0.58) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL7640869 | 0.86 | TSHR (0.54) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL9210392 | 0.86 | RAB9A (0.55) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL28547278 | 0.85 | MAOB (0.70) | MEN1KMT2AALDH1A1MAOBMAOA | |
| SCHEMBL6676703 | 0.85 | MAPT (0.55) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL10936594 | 0.84 | MEN1 (0.63) | MEN1KMT2ATSHRALDH1A1MAOB | |
| SCHEMBL9217552 | 0.83 | SIGMAR1 (0.60) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743082-A1 | CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION | UCL Business Ltd (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| US-20250375428-A1 | CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER | HOTSPOT THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4637749-A2 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250161278-A1 | CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION | HOTSPOT THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4554586-A1 | CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER | Hotspot Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4554582-A1 | CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION | Hotspot Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| CN-1307567-A | 1,5 benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2001-08-08 | — | — | CN | disclosed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| CN-1232452-A | NMDA (N-methyl-D-aspartate) antagonists | HOECHST MARION ROUSSEL INC (US) | 1999-10-20 | — | — | CN | disclosed |
| US-5633270-A | Thiazolidine derivatives, preparation thereof and drugs containing samem | RHONE-POULENC RORER S.A. (FR) | 1997-05-27 | — | — | US | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
| US-4288364-A | REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | MEN1 436/4885KMT2A 2857/4885TSHR 4612/4885 |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | MEN1 4166/4885KMT2A 2417/4885TSHR 939/4885 |
| US-20250161278-A1 | CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION | CBLB, CBL, CBLC | MEN1 2263/4885KMT2A 1529/4885TSHR 3883/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | MEN1 859/4885KMT2A 663/4885TSHR 2934/4885 |
| US-20250375428-A1 | CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER | CBLB, CBL, CBLC | MEN1 3610/4885KMT2A 961/4885TSHR 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.